Background: Hepatitis delta virus (HDV) infection produces the most severe form of chronic viral hepatitis. Treatment with peginterferon gives only limited benefit on delta hepatitis. Since HDV replication requires HBsAg and tenofovir is amongst the most potent anti-HBV agents and is widely used as part of HIV therapy, we explored whether prolonged tenofovir (TDF) exposure might be of benefit on hepatitis delta. Methodology: All HIV-infected patients with hepatitis delta treated with TDF followed at an HIV clinic in Spain were retrospectively identified. Serum HBV/HDV-RNA was quantified using a commercial real-time PCR assay. Liver fibrosis was measured using elastometry (FibroScan). Significant liver fibrosis regression (sLFR) was defined as a 30% reduction in hepatic stiffness compared to baseline. Results: A total of 19 HIV-infected patients with hepatitis delta were identified. HCV antibodies were present in 16 (84%), although HCV-RNA was detectable only in 3 (2%). Overall 79% were former intravenous drug users; 95% male; median age 48 years-old. HDV genotype 1 was present in all cases. HBV genotypes D and A were the most common (53% and 26%, respectively). Prior lamivudine exposure (median 59 months) before beginning TDF was recognized in 9 (47%), being the rest naive for any anti-HBV agent. After a median TDF exposure of 58 [34-93] months, all achieved undetectable HBV-DNA and 10 (53%) reached HDV-RNA <10 copies/mL. In the last group, the median time for the achievement of undetectable HDV-RNA was 54 [33-72] months. Of note, in the subset of HDV viremic patients at the end of follow-up there was also a median drop in HDV-RNA of 2.42 [1.27 - 3.09] log cop/mL. sLFR was recognized in 6 (60%) out of 10 patients who achieved undetectable HDV-RNA and in none of 9 that remained viremic at the end of follow-up (p=0.02). Median liver enzymes slightly declined during the study period, but normalized in only 3. There were no significant changes in serum HBsAg levels during the study period, although HBsAg seroclearance occurred in 2 patients, who became negative for serum HDV-RNA. Conclusions: Long-term exposure to TDF significantly reduces serum HDV-RNA besides completely suppress HBV-DNA in HIV-infected patients with hepatitis delta. This effect is accompanied by significant liver fibrosis regression.